

1 **TITLE**

2

3 The SUMO protease Ulp2 regulates genome stability and drug resistance in the  
4 human fungal pathogen *Candida albicans*

5

6

7 Marzia Rizzo<sup>1</sup>, Natthapon Soisangwan<sup>2</sup> Jan Soetaert <sup>3</sup>, Samuel Vega-Estevez<sup>1</sup>,  
8 Anna Selmecki <sup>2</sup> and Alessia Buscaino<sup>1#</sup>

9

10 <sup>1</sup> University of Kent, School of Biosciences, Kent Fungal Group, Canterbury Kent,  
11 CT2 7NJ, UK.

12 <sup>2</sup> University of Minnesota, Department of Microbiology and Immunology, Minneapolis,  
13 Minnesota, United States, 55455

14 <sup>3</sup> Blizard Advanced Light Microscopy (BALM), Queen Mary University of London,  
15 London E12AT, UK

16 # Address correspondence to Alessia Buscaino

17 Email: [A.Buscaino@kent.ac.uk](mailto:A.Buscaino@kent.ac.uk)

18

19

20

21

22

23

## 24     **Abstract**

25     Stress-induced genome instability in microbial organisms is emerging as a critical  
 26     regulatory mechanism for driving rapid and reversible adaption to drastic  
 27     environmental changes. In *Candida albicans*, a human fungal pathogen that causes  
 28     life-threatening infections, genome plasticity confers increased virulence and  
 29     antifungal drug resistance. Discovering the mechanisms regulating *C. albicans*  
 30     genome plasticity is a priority to understand how this and other microbial pathogens  
 31     establish life-threatening infections and develop resistance to antifungal drugs. We  
 32     identified the SUMO protease Ulp2 as a critical regulator of *C. albicans* genome  
 33     integrity through genetic screening. Deletion of *ULP2* leads to hypersensitivity to  
 34     genotoxic agents and increased genome instability. This increased genome diversity  
 35     causes reduced fitness under standard laboratory growth conditions but enhances  
 36     adaptation to stress, making *ulp2Δ/Δ* cells more likely to thrive in the presence of  
 37     antifungal drugs. Whole-genome sequencing indicates that *ulp2Δ/Δ* cells counteract  
 38     antifungal drug-induced stress by developing segmental aneuploidies of  
 39     chromosome R and chromosome I. We demonstrate that intrachromosomal  
 40     repetitive elements drive the formation of complex novel genotypes with adaptive  
 41     power.

42

## 43 Introduction

44 Understanding how organisms survive and thrive in changing environments is a  
 45 fundamental question in biology. Genetic variation is central to environmental  
 46 adaptation as it allows selection of certain genotypes better fit to grow in new  
 47 environments. Different types of genetic change contribute to genetic variability,  
 48 including (i) mutations such as single-base alteration and small (<100 bp) insertions  
 49 or deletions (indels), (ii) large (>1 kb) deletions and duplications, (iii) whole-  
 50 chromosome or segmental-chromosome aneuploidy and (iv) translocations and  
 51 complex genomic rearrangements [1]. Furthermore, diploid cells can undergo Loss  
 52 of Heterozygosity (LOH) driven by cross-overs or gene conversions between the two  
 53 homologous chromosomes [2]. Excessive genome instability is harmful in the  
 54 absence of selective pressure as it alters the copy-number of many genes, leading to  
 55 unbalanced protein levels [3]. However, an unstable genome can provide rapid  
 56 adaptive power in hostile environments [4,5] because it provides genetic diversity  
 57 upon which selection can act.

58 Genome plasticity – the ability to generate genomic variation – is emerging as a  
 59 critical adaptive mechanism in human microbial pathogens that need to adapt rapidly  
 60 to extreme environmental shifts, including changes in temperature, pH and nutrient  
 61 availability following colonisation of different host environments [6,7]. One such  
 62 organism is *Candida albicans*, the most common human fungal pathogen and the  
 63 most prevalent cause of death due to fungal infection. *C. albicans* is part of the  
 64 normal microflora of most healthy individuals where it colonises the skin, mucosal  
 65 surface, gastrointestinal and the female genitourinary tract. However, *C. albicans*  
 66 can become a dangerous pathogen causing a wide range of infections, from  
 67 superficial mucosal infections to life-threatening disseminated diseases [8]. Azole  
 68 antifungal agents, such as Fluconazole (FLC), are the most commonly prescribed  
 69 drugs for treating *Candida* infections [9–11]. FLC targets the enzyme lanosterol 14 $\alpha$ -  
 70 demethylase, encoded by *ERG11*, blocking biosynthesis of ergosterol, an essential  
 71 component of the fungal cell membrane [12,13]. As a result, FLC arrests *C. albicans*  
 72 cell growth without killing the fungus. This fungistatic, rather than fungicidal, mode of  
 73 action allows for the evolution of drug-resistant strains [14]. One primary mechanism  
 74 of drug resistance is an increased production of the FLC target, Erg11 enzyme,  
 75 diluting the activity of the drug [12]. This high target production is often due to

increased activity of the transcription factor Upc2 activating *ERG11* transcription [15–18]. Overproduction of efflux pumps, such as the *C. albicans* proteins Cdr1, Cdr2 and Mdr1, can also drive FLC resistance by decreasing intracellular FLC levels [19]. In recent years, genome plasticity has emerged as a critical adaptive mechanism causing antifungal drug resistance. *C. albicans* is a diploid organism with a highly heterozygous genome organised into  $2 \times 8$  chromosomes ( $2n = 16$ ) [20,21]. Population studies have identified a remarkable genomic variation among *C. albicans* isolates and specific chromosomal variations are selected during host-niche colonisation [22–28]. Indeed, many drug-resistant isolates exhibit karyotypic diversity, including aneuploidy and gross chromosomal rearrangements that can confer resistance due increased copy number of specific genes including *ERG11*, and/or multidrug transporters [7,29,30].

*C. albicans* genome instability is not random: it occurs more frequently at specific hotspots that are often repetitive [31–35]. Subtelomeric regions and the *rDNA* locus are among the most unstable genomic sites [34,36]. Indeed, *C. albicans* subtelomeric regions are enriched in transposons-derived repetitive sequences and protein-coding genes [31,37]. Most notable are the telomere-associated *TLO* genes, a family of 14 closely related paralogues encoding proteins similar to the Mediator 2 subunit of the mediator transcriptional regulator [38–40]. The majority of *TLO* genes are located at subtelomeric regions except *TLO34*, located at an internal locus on the left arm of Chr1 [38]. The number and position of *TLO* genes vary widely between clinical isolates, indicating significant plasticity with potential consequences for the fitness of the organism [34]. The *rDNA* locus consists of a tandem array of a ~12 kb unit repeated 50 to 200 times on chromosome R; rDNA length polymorphisms occur frequently [21,34]. In addition to these complex repetitive elements, different types of Long Repeat Sequences (65 bp to 6.5 Kb) dispersed across the *C. albicans* genomes have been shown to drive karyotype variation during adaptation to antifungal drugs and passage through the mouse host [32,33].

*C. albicans* genome plasticity is regulated by environmental conditions: the genome is relatively stable under optimal laboratory growth conditions but becomes more unstable under stress conditions [41,42]. For example, FLC treatment drives a global increase in LOH, chromosome rearrangements and aneuploidy [41,42]. This increased genetic variation facilitates selection of fitter genotypes [28,29]. Similarly,

higher rates of genomic variation are detected following passage of *C. albicans* *in vivo* relative to passage *in vitro* [35,43]. It is unknown if and how stress regulates genome plasticity. The discovery of such regulatory mechanisms will be essential to reveal how resistance to antifungal drugs emerges.

This study posits that gene deletions for critical regulators of *C. albicans* genome integrity would cause higher genome variation and rapid adaptation to FLC. To test this hypothesis, we performed a genetic screen to identify modulators of *C. albicans* genome stability. The screen led to the identification of the SUMO protease Ulp2. In the absence of stress, *ULP2* deletion leads to elevated genome instability causing fitness defects and hypersensitivity to genotoxic agents. In contrast, the elevated genome instability of the *ulp2*  $\Delta/\Delta$  strain is advantageous in the presence of high FLC doses. This is because the increased genetic diversity expands the pool of genotypes upon which selection can act, driving adaptation to a new stress environment (FLC), concomitantly rescuing the fitness defects associated with *ULP2* deletion. We also demonstrate that intrachromosomal repetitive elements are sites of genetic diversity that drive the formation of complex novel genotypes with adaptive potential.

## Results

### ***A systematic genetic screen identifies the Ulp2 as a regulator of C. albicans genotoxic stress response***

To identify factors regulating *C. albicans* genome integrity, we utilised a deletion library comprising a subset (674/3000) of *C. albicans* genes that are not conserved in other organisms or have a functional motif potentially related to virulence [44]. As defects in genome integrity lead to hypersensitivity to genotoxic agents [45], the deletion library was screened for hypersensitivity to two DNA damaging agents: Ultraviolet (UV) irradiation which induces formation of pyrimidine dimers [46], and Methyl MethaneSulfonate (MMS), which leads to replication blocks and base mispairing [47].

Genotoxic stress hypersensitivity was semi-quantitatively scored by comparing the growth of treated versus untreated on a scale of 0 to 4, where 0 indicates no sensitivity, and 4 specifies strong hypersensitivity (**Fig 1A**). The screen identified 32 gene deletions linked to DNA damage hypersensitivity (UV or MMS score  $\geq 2$ ).

Almost half of these hits (14/32; ~44%) are genes predicted to encode components of the DNA Damage Response pathway (7/32; ~22%) or the cell division machinery (7/32; ~22%) (**Table S1**). For example, the top 4 hits of the screen were *MEC3*, *RAD18*, *GRR1* and *KIP3* genes. Although *C. albicans* *MEC3* and *RAD18* are uncharacterised, they encode for proteins, conserved in other organisms, that are universally involved in sensing DNA damage (Mec3) [48] and in DNA post-replication repair (Rad18) [49]. *C. albicans* *GRR1* and *KIP3* are required for cell cycle progression [50] and mitotic spindle organisation, respectively [51] (**Fig 1B** and **Table S1**). ~25% (8/32) of the remaining hits are genes encoding proteins with no apparent orthologous in the two well-studied yeast model systems (*S. cerevisiae* and *S. pombe*). This high percentage is not surprising as one of the criteria used to select target genes for the deletion library was the lack of conservation between *C. albicans* and yeast model systems [44]. The remaining 10 hits are genes encoding for proteins with diverse functions, including stress response (*HOG1*) [52], transcriptional and chromatin regulation (*SPT8*, *SET3*) [53–55], transport (*YPT7*, *DUR35*, *NPR2*, *FCY2*) [56–59], protein folding (*HCH1*) [60], MAP kinase pathway (*STT4*) [61] and cell wall biosynthesis (*KRE5*) [62].

One of the highest-ranked genes on our screen is *ULP2* (CR\_03820C/ *orf19.4353*: EMS score:3, UV score:3) encoding for a SUMO protease (**Fig 1C**). SUMOylation is a dynamic and reversible post-translation modification in which a member of the SUMO family of proteins is conjugated to target proteins at lysine residues by E1 activating enzymes, E2 conjugating enzymes and E3 ligases [63–65]. SUMO proteases remove the polypeptide SUMO from target proteins, regulating their function, activity or localisation [66,67].

*C. albicans* *ULP2* is an excellent candidate for a modulator of stress-induced genome plasticity for several reasons: (i) post-translation modifications (PTMs), such as SUMOylation, are rapid and reversible. Consequently, PTMs can modulate genome instability in response to rapid and transient environmental changes [68,69], (ii) protein sumoylation is emerging as a critical stress response mechanism across eukaryotes [66,70–73] (iii) *C. albicans* protein sumoylation levels change in response to environmental stresses encountered in the host [74].

Colony-Forming Unit (CFU) assays of UV-treated cells confirm the importance of *ULP2* in DNA damage resistance as UV treatment reduced the number of CFU in a *ulp2*  $\Delta/\Delta$  strain (~14.5% survival) compared to a wild-type (WT) strain (~33.7%

survival:) (**Fig 1D**). Furthermore, the *ulp2*  $\Delta/\Delta$  strain also displayed a reduced growth rate in liquid media containing MMS or Hydroxyurea (HU), a chemotherapeutic agent that challenges genome integrity by stalling replication forks [75] (**Fig 1E and 1F**). Thus, *ULP2* has a role in the response to a wide range of genotoxic agents.

### ***ULP2 but not ULP1 is required for survival under stress***

*C. albicans* contains three putative SUMO-deconjugating enzymes: Ulp1, Ulp2 and Ulp3 (**Fig 2A**). Sequence comparison between the three *C. albicans* Ulp proteins and the two *S. cerevisiae* Ulps (Ulp1 and Ulp2) reveals that although the *C. albicans* proteins are poorly conserved, the amino acid residues essential for catalytic activity are conserved. This analysis suggests that all *C. albicans* Ulps are active SUMO proteases (**Fig 2A and 2B**). Accordingly, recombinantly expressed *C. albicans* Ulp1, Ulp2 and Ulp3 have SUMO-processing activity *in vitro* [76]. Similarly to *S. cerevisiae* *ULP1*, *C. albicans* *ULP3* is an essential gene and was not investigated further in this study [77].

Previous studies suggested that *C. albicans* Ulp2 is an unstable or a very low abundant protein undetectable by Western blot analysis [76]. We reassessed *ULP2* expression by generating strains expressing, at the endogenous locus, an epitope-tagged Ulp2 protein (Ulp2-HA). Western analyses show that Ulp2-HA expression is readily detected in extracts from independent integrant strains. (**Fig 2C**). Thus, a stable Ulp2 protein is expressed in cells grown under standard laboratory growth conditions (YPD, 30 °C). To assess whether *C. albicans* *ULP1* and *ULP2* gene share a similar function, we engineered homozygous deletion strains for *ULP1* (*ulp1* $\Delta/\Delta$ ) and *ULP2* (*ulp2* $\Delta/\Delta$ ). Growth analysis demonstrated that deletion of *ULP2* reduces fitness as the newly generated *ulp2* $\Delta/\Delta$  strain is viable, but cells are slow-growing (**Fig 2D and 2E**). In contrast, the *ulp1* $\Delta/\Delta$  strain grows similarly to the WT control in solid and liquid media (**Fig 2D and 2E**). Phenotypic analysis confirms that *ULP2* is an important regulator of *C. albicans* stress response as, similarly to the deletion library mutant, the newly generated *ulp2*  $\Delta/\Delta$  strain is sensitive to different stress conditions including treatment with DNA damaging agents (UV and MMS), DNA replication inhibitor (HU), oxidative stress (H<sub>2</sub>O<sub>2</sub>) and high temperature (39°C) (**Fig 2E**) In contrast, deletion of *ULP1* did not cause any sensitivity to the tested stress conditions (**Fig 2E**).



In summary, we could not detect any phenotype associated with deletion of *ULP1*, while loss of *ULP2* leads to poor growth in standard laboratory growth conditions and hypersensitivity to multiple stresses.

### ***Loss of ULP2 leads to increased genome instability***

To assess whether the hypersensitivity to DNA damage agents observed in the *ulp2Δ/Δ* strain was indeed due to enhanced genome instability, we deleted the *ULP2* gene from a set of tester strains containing a heterozygous *URA3*<sup>+</sup> marker gene inserted in three different chromosomes (Chr 1, 3 and 7) [41]. We quantified the frequency of *URA3*<sup>+</sup> marker loss by plating on plates containing the *URA3* counter-selective drug FOA and scoring the number of colonies able to grow on FOA-containing media compared to non-selective (N/S) media. Deletion of *ULP2* leads to a dramatic increase in LOH rate at all three chromosomes (Chr1: ~5000X, Chr3: ~18X, Chr7: ~170X), indicating that *ULP2* is required for maintaining genome stability across the *C. albicans* genome (**Fig 3A**).

In *C. albicans*, hypersensitivity to genotoxic stress often correlates with filamentous growth [45,78–81]. Accordingly, and in agreement with a significant role for *ULP2* in genotoxic stress response, the *ulp2Δ/Δ* strain displays a higher frequency of abnormal morphologies than a WT strain, including filamentous pseudohyphal-like and hyphal-like cells (**Fig 3B**). To assess whether the exacerbated *ulp2Δ/Δ* genome instability is linked to defective chromosome segregation, we deleted the *ULP2* gene in a reporter strain in which *TetO* sequences are integrated adjacent to the centromere (*CEN7*) of one Chromosome 7 homolog and TetR-GFP fusion protein is expressed from an intergenic region [82]. Binding of TetR-GFP to *tetO* sequences allowed visualisation of Chr7 duplication and segregation during the cell cycle. We found that deletion of *ULP2* leads to abnormal Chr7 segregation, including cells with no TetR-GFP signals or multiple TetR-GFP-foci, which was ~5 fold higher in the *ulp2Δ/Δ* strain than the WT control strain (**Fig 3C**).

Previous studies performed in the model system *S. cerevisiae* demonstrated that loss of *ULP2* leads to the accumulation of a specific multichromosome aneuploidy (amplification of both ChrI and ChrXII) that rescues the potential lethal defects of *ulp2* deletion by amplification of specific genes on both chromosomes [83,84]. To determine whether loss of *C. albicans* *ULP2* results in a specific aneuploidy, we



sequenced the genome of 3 randomly selected *ulp2*  $\Delta/\Delta$  colonies by whole genome sequencing (WGS) and compared their genome sequences to the *C. albicans* reference genome. This analysis demonstrates that deletion of *C. albicans* *ULP2* does not select for specific chromosome rearrangements and identifies different genomic variations that are not present in the parental WT strain (**Fig 3D** and **Table S2**) [85]. While deletion of *ULP2* leads to very few (<10) *de novo* mutations (**Table S2**), two of the three colonies underwent extensive LOH on different chromosomes (**Fig 3D** and **Table S2**). For example, chromosome missegregation followed by reduplication of the remaining homologue is detected on isolate C1 (C1: ChrR) and the genome of C2 contains a long-track LOH (C2:Chr 3L) that occurred within 4.6 kb of a repeat locus on Chr3L (*PGA18*, [32]) (**Fig 3D**). Our analysis collectively demonstrates that deletion of *C. albicans* *ULP2* leads to increased genome instability via the formation of extensive chromosomal variation.

### ***Loss of ULP2 leads to drug resistance via selection of novel genotypes***

We hypothesised that the increased genome instability of the *ulp2*  $\Delta/\Delta$  strain would facilitate adaptation to hostile environments via selection of fitter genotypes. To test this hypothesis, we assessed whether WT and *ulp2*  $\Delta/\Delta$  strains differ in their ability to overcome the stress imposed by low or high concentrations of 2 drugs: Fluconazole (FLC) and caffeine (CAF). FLC was chosen because it is the most used antifungal drug in the clinic. CAF was chosen because it is associated with well-known resistance mechanisms [86,87]. Serial dilution analyses demonstrate that the *ulp2*  $\Delta/\Delta$  strain is not sensitive to a low FLC (15  $\mu$ g/ml) dose while it is sensitive a low CAFF (5mM) doses (**Fig 4A** and **4B**).

In contrast, deletion of *ULP2* increases adaptation to high doses FLC and CAF. On plates containing an inhibitory concentration of FLC (128  $\mu$ g/ml), a WT strain produced only tiny abortive colonies while the *ulp2*  $\Delta/\Delta$  strain produces colonies of heterogenous size (Large and Small, **Fig 4C**). The starting *ulp2*  $\Delta/\Delta$  strain is highly sensitive to 12 mM CAF (**Fig S1A**), and therefore a reduced number of *ulp2*  $\Delta/\Delta$  colonies grew at this high drug concentration compared to the WT strain (**Fig 4D**). Despite this difference, the *ulp2*  $\Delta/\Delta$  strain, but not the WT strain, produces large colonies that can grow on high CAF concentration following passaging in the

absence of the drug, indicative of adaptation (**Fig 4D, Fig S1B**). Thus, deletion of *ULP2* accelerates adaptation to lethal drug concentration.

To test whether enhanced drug adaption was linked with selection of novel genotypes, we sequenced the genome of 4 independent *ulp2Δ/Δ* FLC-adapted isolates (*FLC-1*, *FLC-2*, *FLC-3* and *FLC-4*). *FLC-1*, *FLC-2* and *FLC-3* were randomly selected from the High FLC plates and sequenced immediately. In contrast, *FLC-4* was selected because this isolate was still able to grow on high FLC following passaging in non-selective (N/S) media (**Fig S1C**). To assess for genotype heterogeneity, three *FLC-4* derived single colonies (*FLC-4a*, *b* and *c*) were sequenced (**Fig S2A and B**). The WGS analysis demonstrates that all FLC-adapted colonies have a genotype that is distinct from the *ulp2 Δ/Δ* progenitor. We detected very few (<10) *de novo* point mutations, and none of these are common among all the sequenced FLC isolates (**Table S3**). In contrast, all colonies are marked by an extensive segmental chromosome aneuploidy: a partial deletion (~ 388 Kb) of the right arm of Chromosome R (ChrRR-Deletion). ChrRR-deletion occurs at the ribosomal DNA (25S subunit) and it extends to the right telomere of ChrR (ChrR:1,897,750 bp - 2,286,380 bp), reducing the dosage of 204 genes (**Fig 4E, S2A and Table S4**). GO analysis revealed that ChrRR-Deletion leads to a reduced dosage of 34/204 genes associated with the "response to stress" pathways and 18/204 genes linked to "response to drug" pathways (**Table S4**). We posit that this reduced gene dosage enables growth in the presence of high FLC. For example, *CKA1*, a gene whose deletion leads to FLC resistance [88], is located within the ChrRR-deletion (**Fig 4G**).

Interestingly, we found that all three *FLC-4* sequences colonies (*FLC-4a*, *b* and *c*), are marked by a second segmental aneuploidy: a partial Chr1 amplification (Chr1-Duplication) (**Fig 4E and S2A**). This novel Chr1-Duplication amplifies a genomic fragment of ~1.3 Mbp containing 535 protein-coding genes (**Table S4**). The Chr1-Duplication starts and ends near two distinct DNA repeat sequences with high sequence identity elsewhere in the genome: the 5' breakpoint is within the *TLO34* and its 3' breakpoint is within 3 kb of a *Zeta-1a* Long Terminal Repeat (LTR) (**Fig 4G and S3**) [32,33,89]. These WGS data led us to hypothesise that a chromosome-chromosome fusion event occurred between the Chr1-Duplication and Chr6 within homologous *TLO* sequences (**Fig 4G**). Indeed, the *TLO34* gene on Chr1 has high

sequence identity with a 380 bp region located at Chr6 (position: 6182-6562 bp). In addition, sequence polymorphisms unique to Chr1-*TLO34* mapped to Chr6 in the *FLC-4* isolate (but not in *FLC-1*, *FLC-2* and *FLC-3*), supporting a novel interchromosomal recombination product between *TLO*-homologous sequences. This model is supported by CHEF gel electrophoresis analyses as, when compared to the *ulp2*  $\Delta/\Delta$  progenitor, the *FLC-4* genome lacks one band corresponding to the shorter Chr6 homologue (blue asterisk), and it contains a new chromosome band of ~2.2 Mb (magenta asterisk) (**Fig 4F**).

We posit that Chr1-Duplication provides a synergistic fitness advantage in response to two independent stressors (the presence of FLC and lack of *ULP2*) by simultaneously changing the dosage of several genes. Indeed, GO analyses demonstrated that 41 genes present in the Chr1-Duplication are associated with a "drug resistance" phenotypes (**Table S4**). Among these, amplification of *UPC2* encoding for the Upc2 transcription factor is likely to be critical. Indeed, it is well established that *UPC2* overexpression leads to FLC resistance by *ERG11* upregulation [90,91]. Chr1-Duplication likely rescues the fitness defects of the *ulp2*  $\Delta/\Delta$  strain by amplifying two key genes: *CCR4* and *NOT5* (**Fig 4G**). Ccr4 and Not5 are subunits of the evolutionarily conserved Ccr4-Not complex that modulate gene expression at multiple levels, including transcription initiation, elongation, de-adenylation and mRNA degradation [92]. It has been shown that *S. cerevisiae* *CCR4* and *NOT5* overexpression rescue the lethal defects associated with a *ulp2* deletion strain [83].

Collectively our data suggest that the combined selective pressure of two independent stresses leads to selection of a chromosome aneuploidy that overcomes both stresses by overexpressing two different sets of genes.

## Discussion

In this study, we demonstrate that the SUMO protease Ulp2 is a critical regulator of *C. albicans* genome plasticity and that the development of drug resistance is accelerated in cells lacking *ULP2*. We unveil a striking flexibility of *C. albicans* cells in their response to complex stresses caused by drug treatment and dysregulation of the SUMO system, leading to the selection of extensive chromosome rearrangements.

### ***Ulp2 is a critical regulator of C. albicans genome stability***

Our study identifies protein SUMOylation as a critical regulatory mechanism of *C. albicans* genome stability. SUMOylation is a dynamic and reversible post-translation modification in which a member of the SUMO family of proteins is conjugated to target proteins at lysine residues by E1 activating enzymes, E2 conjugating enzymes and E3 ligases [63–65]. SUMO is removed from its target proteins by SUMO-specific Ulp2 proteases [67]. Several observations are in agreement with our findings and suggest that SUMOylation controls stress-induced genome plasticity. Firstly, SUMOylation is a post-translational modification that is rapid and reversible, an essential requirement for a regulator of stress-induced genome plasticity. Secondly, *C. albicans* protein SUMOylation levels are different in normal and stress growth conditions [74]. Thirdly, deletion of genes encoding other components of the *C. albicans* SUMOylation machinery lead to filamentation, a phenotype often associated with defective cell division and compromised genome integrity [74,93,94]. Finally, *C. albicans* strains lacking the SUMO (Smt3) protein or the E3 ligase Mms21 display nuclear segregation defects [74,93].

*C. albicans* Ulp2 likely controls genome plasticity by modulating SUMO levels of several target proteins. SUMO proteases have a broad substrate specificity catalysing SUMO deconjugation of several substrates [95]. In other organisms, it is well known that SUMOylation modulates pathways ensuring genome integrity, including the DNA damage-sensing and repair pathway and the cell division and chromosome segregation pathway [63–66,96–98]. Despite the broad substrate specificity, our data suggest that one significant function of *C. albicans* *ULP2* is to ensure faithful chromosome segregation as high rates of chromosome missegregation is detected in the *ulp2*  $\Delta/\Delta$  strain. Furthermore, the Illumina Genome sequencing analyses demonstrated that lack of *ULP2* is associated with extensive LOH events. Such extensive genomic changes are reminiscent of catastrophic mitotic events associated with defective chromosome segregation [99,100]. The targets of *C. albicans* Ulp2 are unknown, and it will be important to adopt proteomic approaches to identify the entire repertoire of SUMO targets and determine how *ULP2* contributes to *C. albicans* genome plasticity.

## **Complex chromosome rearrangements drive adaptation to multiple stress environments.**

Our data demonstrate that the *ulp2*  $\Delta/\Delta$  strain is more likely than the WT parental strain to develop resistance to anti-fungal drugs by selecting specific segmental aneuploidies on ChrR (ChrRR-deletion) and Chr1 (Chr1-duplication). These adaptive genotypes confer a growth advantage in response to two independent stressors: the absence of *ULP2* and drug treatment.

In agreement with the notion that repetitive elements play a significant role in genome instability, we identified intrachromosomal repetitive elements as drivers of genome instability. Indeed, all the sequenced *FLC*-adapted isolates carry a partial deletion of ChrR originating within the rDNA locus. We have previously demonstrated that the *C. albicans* rDNA locus is a hotspot for mitotic recombination [36], and clinical isolates are often marked by chromosomal aberrations originating from this locus [34]. This rDNA-driven chromosomal aberration leads to the deletion of one copy of 204 genes. We hypothesise that this reduced gene dosage drives *FLC* adaptation. For example, *CKA1*, one of the genes affected by ChrRR deletion, encodes for one of the two *C. albicans* Casein Kinases (Cka1 and Cka2). Deletion of these genes causes *FLC* resistance by controlling the expression of the efflux pump *CDR1* and *CDR2* [88].

WGS analysis demonstrated that the *FLC-4* isolate, whose *FLC* resistance is maintained followed by passaging on non-selective media, carries a second segmental aneuploidy: a partial duplication of Chr1 with breakpoints at repetitive elements. We provide evidence suggesting that Chr1 Duplication results from a fusion event between Chr1 and Chr6 due to a novel interchromosomal recombination product between *TLO* homologous sequences. We hypothesise that Chr1-duplication leads to gene dosage changes that are critical for overcoming two independent stresses: the presence of *FLC* and the absence of *ULP2*. Indeed, one of the master regulators of *FLC* resistance, *UPC2*, is located on the Chr1-duplication and its overexpression is likely to allow growth in the presence of *FLC*. *UPC2* encodes a key transcription factor of *ERG11*, the target of *FLC* [91]. It is well established that *UPC2* deletion leads to increased *FLC* susceptibility and that *UPC2*

overexpression causes FLC resistance [91,101]. Accordingly, *UPC2* gain-of-function mutations are prevalent among FLC resistant clinical isolates [101]. The Chr1-duplication carries two key genes, *CCR4* and *NOT5*, likely to rescue the fitness defects associated with the *ulp2 Δ/Δ* strain. Indeed, it has been shown that *CCR4* and *NOT5* overexpression rescues the fitness defects of a *ULP2* deletion strain in *S. cerevisiae* [83]. Crr4 and Not5 are components of the evolutionarily conserved Crr4-Not multiprotein complex that regulate gene expression at all steps from transcription to translation and mRNA decay [102]. It is unknown why overexpression of the Crr4-Not complex rescues the fitness defect of an *ulp2* deletion strain, but it has been suggested that it might be linked to the transcriptional regulation of snoRNA and rRNA genes [84]. Here, for the first time, we demonstrate that segmental aneuploidy can lead to adaptation to different stressors by overexpressing genes located in the same chromosome and independently rescue the two stressors, leading to an overall fitness advantage.

## Material and Methods

### ***Yeast strains and Growth Conditions***

Strains used in this study are listed in **Table S5**. Routine culturing was performed at 30 °C in Yeast Extract-Peptone-D-Glucose (YPD) liquid and solid media containing 1% yeast extract, 2% peptone, 2% dextrose, 0.1 mg/ml adenine and 0.08 mg/ml uridine, Synthetic Complete (SC-Formedium) or Casitone (5 g/L Yeast extract, 9 g/L BactoTryptone, 20 g/L Glucose, 11.5 g/L Sodium Citrate dehydrate, 15 g/L Agar) media. When indicated, media were supplemented with 1mg/ml 5-Fluorotic acid (5-FOA, Melford), 200 µg/ml Nourseothricin (clonNAT, Melford), 5mM and 12 mM Caffeine (Sigma #C0750), 15 mg/ml and 128 mg/ml Fluconazole (Sigma #F8929), 6m H<sub>2</sub>O<sub>2</sub> (Sigma #H1009), 12 mM and 22 mM Hydroxyurea (Sigma #H8627), 0.005% MMS (Sigma #129925).

### ***Genetic Screening***

The genetic screening was performed using a *C. albicans* homozygous deletion library [44] arrayed in 96 colony format on YPD plates (145x20 mm) using a replica plater (Sigma #R2508). Control N/S plates were grown at 30 °C for 48 hours. UV treatment was performed using UVitec (Cambridge) with power density of 7.5µW/cm<sup>2</sup> (0.030 J for 4 seconds). Following UV treatment, plates were incubated in the dark at 30°C for 48 hours. For MMS treatment, the library was spotted on YPD



plates (145x20mm) containing 0.05% MMS and incubated at 30°C for 48 hours. UV and/or MMS sensitivity of selected strains was confirmed by serial dilution assays in control (YPD) and stress (UV: power density of 7.5 $\mu$ W/cm<sup>2</sup>, MMS: 0.05% ) plates. Correct gene deletions were confirmed by PCR using gene-specific primers (**Table S6**).

#### ***Yeast strain construction***

Integration and deletion of genes were performed using long oligos-mediated PCR for gene deletion and tagging [103]. Oligonucleotides and plasmids used for strain constructions are listed in Supplementary **Table S6** and **S7**, respectively. For Lithium Acetate transformation, overnight liquid yeast cultures were diluted in fresh YPD and grown to OD<sub>600</sub> of 1.3. Cells were harvested by centrifugation and washed once with dH<sub>2</sub>O and once with SORB solution (100mM Lithium acetate, 10mM Tris-HCL pH 7.5, 1mM EDTA pH 7.5/8, 1M sorbitol; pH 8). The pellet was resuspended in SORB solution containing single-stranded carrier DNA (Sigma-Aldrich) and stored -80 °C in 50  $\mu$ L aliquots. Frozen competent cells were defrosted on ice, mixed with 5  $\mu$ L of PCR product and 300  $\mu$ L PEG solution (100mM Lithium acetate, 10mM Tris-HCL pH 7.5, 1mM EDTA pH 8, 40% PEG4000) and incubated for 21-24 hours at 30 °C. Cells were heat-shocked at 44°C for 15 minutes and grown in 5mL YPD liquid for 6 hours before plating on selective media at 30 °C.

#### ***UV survival quantification***

Following dilution of overnight liquid cultures, 500 cells were plated in YPD control plates while 1500 cells were plated in YPD stress plates and UV irradiates with power density of 7.5  $\mu$ W/cm<sup>2</sup> (0.030 J for 4 seconds). Plates were kept in the dark and incubated at 30°C for 48 hours. Colonies were counted using a colony counter (Stuart Scientific). Experiments were performed in 5 biological replicates, and violin plots graphs were generated using R Studio (<http://www.r-project.org/>).

#### ***Growth curve***

Overnight liquid cultures were diluted to 60 cells/ $\mu$ L in 100 $\mu$ L YPD and incubated at 30 °C in a 96 well plate (Cellstar®, #655180) with double orbital agitation of 400 rpm using a BMG Labtech SPECTROstar nanoplate reader for 48 hours. When indicated, YPD media was supplemented with MMS (0.05%) and HU (22 mM). Graphs show the average of 3 biological replicates and error bars show the standard deviation.

#### ***Serial dilution assay***



Overnight liquid cultures were diluted to an OD<sub>600</sub> of 4, serially diluted 1:5 and spotted into agar plates with and without indicated additives using a replica plater (Replica plater for 96-well plates, Sigma Aldrich, #R2383). Images of the plates were then taken using Syngene GBox Chemi XX6 Gel imaging system. Experiments were performed in 3 biological replicates

### **Protein extraction and Western blotting**

Yeast extracts were prepared as described [104] using  $1 \times 10^8$  cells from overnight cultures grown to a final OD<sub>600</sub> of 1.5–2. Protein extraction was performed in the presence of 2% SDS (Sigma) and 4 M acetic acid (Fisher) at 90°C. Proteins were separated in 2% SDS (Sigma), 40% acrylamide/bis (Biorad, 161-0148) gels and transfer into PVDF membrane (Biorad) by semi-dry transfer (Biorad, Trans Blot SD, semi-dry transfer cell). Western-blot antibody detection was used using antibodies from Roche Diagnostics Mannheim Germany (Anti-HA, mouse monoclonal primary antibody (12CA5 Roche, 5 mg/ml) at a dilution of 1:1000, and anti-mouse IgG-peroxidase (A4416 Sigma, 0.63 mg/ml) at a dilution of 1:5000, and Clarity™ ECL substrate (Bio-Rad).

### ***URA3<sup>+</sup> marker loss quantification***

Strains were first streaked on –Uri media to ensure the selection of cells carrying the *URA3<sup>+</sup>* marker gene. Parallel liquid cultures, grown for 16 hours at 30°C in YPD, were plated on synthetic complete (SC) plates containing 1 □mg/ml 5-FOA (5-fluorotic acid; Sigma) and on non-selective SC plates/. Colonies were counted after 2 □days of growth at 30°C, the frequency of the *URA3<sup>+</sup>* marker loss was calculated using the formula  $F = m/M$ , where  $m$  represents the median number of colonies obtained on 5-FOA medium corrected by the dilution factor used and the fraction of culture plated and  $M$  the average number of colonies obtained on YPD corrected by the dilution factor used and the fraction of culture plated [80]. Statistical differences between results from samples were calculated using the Kruskal-Wallis test and the Mann-Whitney U test for *post hoc* analysis. Statistical analysis was performed and violin plots were generated using R Studio (<http://www.r-project.org/>).

### ***Microscopy***

30 ml of yeast cultures (OD<sub>600</sub>=1) grown in SC were centrifuged at 2000 rpm for 5 minute and washed once with dH<sub>2</sub>O. Cells were fixed in 10ml of 3.7% paraformaldehyde (Sigma #F8775) for 15 minutes, washed twice with 10ml of

KPO<sub>4</sub>/Sorbitol (100 mM KPO<sub>4</sub>, 1.2 M Sorbitol) and resuspended in 250 µl PBS containing 10 µg of Dapi. Cells were then sonicated and resuspended in a 1% low melting point agarose (Sigma Aldrich) before mounting under a 22mm coverslip of 0,17µm thickness. Samples were imaged on a Zeiss LSM 880 Airyscan with a 63x/1.4NA oil objective. Airyscan images were taken with a relative pinhole diameter of 0.2 AU (airy unit) for maximal resolution and reduced noise. GFP was imaged with a 488nm Argon laser and 495-550 nm bandpass excitation filter, RFP with a 546nm solid-state diode laser and a 570nm long pass excitation filter. The Dapi channel was imaged on a PMT with standard pinhole of 1AU and brightfield image were captured on the trans-PMT with the same excitation laser of 405nm., Dapi and brightfield images were taken with the same pixel size and bit depth (16bit) as the airyscan images. Images were of a 42.7x42.7µm field of view and with a 33 nm pixel size resolution. z-stacks were taken containing cells of z interval of 500nm. Airyscan Veena filtering was performed with the inbuilt algorithms of Zeiss Zen Black 2.3. Fiji scripts were written to automatically create a maximum intensity projection with standardised intensity scaling for the fluorescence images and overlay them with the best focus image of the brightfield picture. Experiments were performed in 3 biological replicates and >100 cells/replicate were counted.

### ***Drug Selection***

Strains were incubated overnight in casitone liquid media at 30°C with shaking. 10<sup>4</sup> cells were plated in small (10cm) casitone plates or plates containing: (i) 128 µg/mL DMSO (Fluconazole Control), (ii) 128 µg/mL Fluconazole or (iii) 12 mM Caffeine. Plates were incubated at 30°C for 7 days. Colonies able to grow on Fluconazole- or Caffeine-containing plates were streaked in non-selective plates and tested by spotting assay in casitone+ DMSO plates, casitone+Fluconazole or casitone+Caffeine plates. Following incubation at 30°C, plates were imaged using Syngene GBox Chemi XX6 Gel imaging system. Experiments were performed in 3 biological replicates.

### ***Whole-genome sequence analysis***

All genome sequencing data have been deposited in the Sequence Read Archive under BioProject PRJNA781758, Genomic DNA was isolated using a phenol-chloroform extraction as previously described [29]. Paired-end (2 x 151 bp) sequencing was carried out by the Microbial Genome Sequencing Center (MiGS) on

the Illumina NextSeq 2000 platform. Adaptor sequences and low-quality reads were removed using Trimmomatic (v0.33 LEADING:3 Trailing:3 SLIDINGWINDOW:4:15 MINLEN:36 TOPHRED33) [105]. Trimmed reads were mapped to the *C. albicans* reference genome (A21-s02-m09-r08) from the *Candida* Genome Database ([http://www.candidagenome.org/download/sequence/C\\_albicans\\_SC5314/Assembly\\_21/archive/C\\_albicans\\_SC5314\\_version\\_A21-s02-m09-r08\\_chromosomes.fasta.gz](http://www.candidagenome.org/download/sequence/C_albicans_SC5314/Assembly_21/archive/C_albicans_SC5314_version_A21-s02-m09-r08_chromosomes.fasta.gz)). Reads were aligned to the reference using BWA-MEM (v0.7.17) with default parameters [106]. The BAM files, containing aligned reads, were sorted and PCR duplicates removed using Samtools (v1.10 samtools sort, samtools rmdup) [107]. Qualimap (v2.2.1) analysed the BAM files for mean coverage of the reference genome; coverages ranged from 73.7x to 89.3x coverage [108]. Variant detection was conducted using the Genome Analysis Toolkit (Mutect, v2.2-25) [109]. Variants were annotated using SnpEff (V4.3) [110] using the SC5314 reference genome fasta and gene feature file above. Parental variants were removed, and all remaining variants were verified visually using the Integrative Genomic Viewer (IGV, v2.8.2) [111].

### **Read depth and breakpoint analysis**

Whole-genome sequencing data were analysed for copy number and allele ratio changes as previously described [32,33]. Aneuploidies were visualised using the Yeast Mapping Analysis Pipeline (YMAP, v1.0) [112]. BAM files aligned to the SC5314 reference genome as described above were uploaded to YMAP and read depth was determined and plotted as a function of chromosome position. Read depth was corrected for both chromosome-end bias and GC-content. The GBrowse CNV track and GBrowse allele ratio track identified regions of interest for CNV and LOH breakpoints, and more precise breakpoints were determined visually using IGV. LOH breakpoints are reported as the first informative homozygous position in a region that is heterozygous in the parental genome. CNV breakpoints were identified as described previously [32,33].

### **Contour-clamped homogeneous electric field (CHEF) electrophoresis**

Intact yeast chromosomal DNA was prepared as previously described [113]. Briefly, cells were grown overnight, and a volume equivalent to an OD<sub>600</sub> of 7 was washed in 50 mM EDTA and resuspended in 20 µl of 10 mg/ml Zymolyase 100T (Amsbio #120493-1) and 300 µl of 1% Low Melt agarose (Biorad® # 1613112) in 100 mM EDTA. Chromosomes were separated on a 1% Megabase agarose gel (Bio-

Rad) in 0.5X TBE using a CHEF DRII apparatus. Run conditions as follows: 60-120s switch at 6 V/cm for 12 hours followed by a 120-300s switch at 4.5 V/cm for 12 hours, 14 °C. The gel was stained in 0.5x TBE with ethidium bromide (0.5 µg/ml) for 30 minutes and destained in water for 30 minutes. Chromosomes were visualised using a Syngene GBox Chemi XX6 gel imaging system.

## Acknowledgments

We thank Judith Berman for reagents, strains and materials and A. Pidoux for critical reading of the manuscript. This work was supported by BBSRC (BB/T006315/1 to A.B and S.V.E), a University of Kent GTA PhD studentships (to M.R.), a University of Minnesota UMR Fellowship with the Bioinformatics and Computational Biology program (to N.S), the National Institutes of Health (R01AI143689) and Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases Award (#1020388) to A.S.

## References

1. Sui Y, Qi L, Wu JK, Wen XP, Tang XX, Ma ZJ, et al. Genome-wide mapping of spontaneous genetic alterations in diploid yeast cells. *Proc Natl Acad Sci U S A*. 2020;117: 28191–28200. doi:10.1073/pnas.2018633117
2. Bennett RJ, Forche A, Berman J. Rapid Mechanisms for Generating Genome Diversity: Whole Ploidy Shifts, Aneuploidy, and Loss of Heterozygosity. [cited 11 Aug 2021]. Available: <http://perspectivesinmedicine.cshlp.org/>
3. Pavelka N, Rancati G, Zhu J, Bradford WD, Saraf A, Florens L, et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. *Nature*. 2010;468: 321–325. doi:10.1038/nature09529
4. Siegel JJ, Amon A, Koch DH. New Insights into the Troubles of Aneuploidy. *Annu Rev Cell Dev Biol*. 2012;28: 189–214. doi:10.1146/annurev-cellbio-101011-155807
5. Rancati G, Pavelka N, Fleharty B, Noll A, Trimble R, Walton K, et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. *Cell*. 2008;135: 879–93. doi:10.1016/j.cell.2008.09.039

- 594 6. Rancati G, Pavelka N. Karyotypic changes as drivers and catalyzers of cellular  
595 evolvability: A perspective from non-pathogenic yeasts. *Semin Cell Dev Biol.*  
596 2013;24: 332–338. doi:10.1016/j.semcdb.2013.01.009
- 597 7. Selmecki A, Forche A, Berman J. Genomic plasticity of the human fungal  
598 pathogen *Candida albicans*. *Eukaryot Cell.* 2010;9: 991–1008.  
599 doi:10.1128/EC.00060-10
- 600 8. Teoh F, Pavelka N. pathogens How Chemotherapy Increases the Risk of  
601 Systemic Candidiasis in Cancer Patients: Current Paradigm and Future  
602 Directions. doi:10.3390/pathogens5010006
- 603 9. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America.  
604 *Crit Rev Microbiol.* 2010;36: 1–53. doi:10.3109/10408410903241444
- 605 10. Berman J, Krysan DJ. Drug resistance and tolerance in fungi. *Nat Rev*  
606 *Microbiol.* 2020;18: 319–331. doi:10.1038/s41579-019-0322-2
- 607 11. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of  
608 resistance to antifungal drugs challenges human health and food security.  
609 *Science* (80- ). 2018;360: 739–742. doi:10.1126/science.aap7999
- 610 12. Berkow EL, Lockhart SR. Fluconazole resistance in *Candida* species: a current  
611 perspective. *Infect Drug Resist.* 2017;10: 237. doi:10.2147/IDR.S118892
- 612 13. Heimark L, Shipkova P, Greene J, Munayyer H, Yarosh-Tomaine T,  
613 DiDomenico B, et al. Mechanism of azole antifungal activity as determined by  
614 liquid chromatographic/mass spectrometric monitoring of ergosterol  
615 biosynthesis. *J Mass Spectrom.* 2002;37: 265–269. doi:10.1002/jms.280
- 616 14. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, et al.  
617 Fluconazole for the management of invasive candidiasis: Where do we stand  
618 after 15 years? *J Antimicrob Chemother.* 2006;57: 384–410.  
619 doi:10.1093/JAC/DKI473
- 620 15. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J. An  
621 A643T mutation in the transcription factor Upc2p causes constitutive ERG11  
622 upregulation and increased fluconazole resistance in *Candida albicans*.  
623 *Antimicrob Agents Chemother.* 2010;54: 353–359. doi:10.1128/AAC.01102-09

- 624 16. Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, et  
625 al. UPC2A is required for high-level azole antifungal resistance in *Candida*  
626 *glabrata*. *Antimicrob Agents Chemother*. 2014;58: 4543–4554.  
627 doi:10.1128/AAC.02217-13
- 628 17. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD. A  
629 gain-of-function mutation in the transcription factor Upc2p causes upregulation  
630 of ergosterol biosynthesis genes and increased fluconazole resistance in a  
631 clinical *Candida albicans* isolate. *Eukaryot Cell*. 2008;7: 1180–1190.  
632 doi:10.1128/EC.00103-08
- 633 18. Hoot SJ, Smith AR, Brown RP, White TC. An A643V amino acid substitution in  
634 Upc2p contributes to azole resistance in well-characterized clinical isolates of  
635 *Candida albicans*. *Antimicrob Agents Chemother*. 2011;55: 940–942.  
636 doi:10.1128/AAC.00995-10
- 637 19. Morschhäuser J. The development of fluconazole resistance in *Candida*  
638 *albicans* – an example of microevolution of a fungal pathogen. *J Microbiol*.  
639 2016;54: 192–201. doi:10.1007/s12275-016-5628-4
- 640 20. Jones T, Federspiel NA, Chibana H, Dungan J, Kalman S, Magee BB, et al.  
641 The diploid genome sequence of *Candida albicans*. *Proc Natl Acad Sci U S A*.  
642 2004;101: 7329–34. doi:10.1073/pnas.0401648101
- 643 21. van het Hoog M, Rast TJ, Martchenko M, Grindle S, Dignard D, Hogues H, et  
644 al. Assembly of the *Candida albicans* genome into sixteen supercontigs  
645 aligned on the eight chromosomes. *Genome Biol*. 2007;8: R52.  
646 doi:10.1186/gb-2007-8-4-r52
- 647 22. Hirakawa MP, Martinez D a, Sakthikumar S, Anderson MZ, Berlin A, Gujja S,  
648 et al. Genetic and phenotypic intra-species variation in *Candida albicans*.  
649 2015; 1–13. doi:10.1101/gr.174623.114.
- 650 23. Tso GHW, Reales-Calderon JA, Tan ASM, Sem X, Le GTT, Tan TG, et al.  
651 Experimental evolution of a fungal pathogen into a gut symbiont. *Science* (80-  
652 ). 2018;362: 589–595. doi:10.1126/SCIENCE.AAT0537
- 653 24. Forche A, Cromie G, Gerstein AC, Solis N V., Pisithkul T, Srifa W, et al. Rapid



- 654 Phenotypic and Genotypic Diversification After Exposure to the Oral Host  
655 Niche in *Candida albicans*. Genetics. 2018;209: genetics.301019.2018.  
656 doi:10.1534/genetics.118.301019
- 657 25. Forche A, Magee PT, Selmecki A, Berman J, May G. Evolution in *Candida*  
658 *albicans* Populations During a Single Passage Through a Mouse Host.  
659 Genetics. 2009;182: 799–811. Available:  
660 <http://www.genetics.org/content/182/3/799.abstract>
- 661 26. Ene I V., Farrer RA, Hirakawa MP, Agwamba K, Cuomo CA, Bennett RJ.  
662 Global analysis of mutations driving microevolution of a heterozygous diploid  
663 fungal pathogen. Proc Natl Acad Sci. 2018;115: 201806002.  
664 doi:10.1073/pnas.1806002115
- 665 27. Ropars J, Maufrais C, Diogo D, Marcet-houben M, Perin A, Sertour N, et al.  
666 Gene flow contributes to diversification of the major fungal pathogen  
667 *Candida albicans*. 2018. doi:10.1038/s41467-018-04787-4
- 668 28. Forche A, Solis N V., Swidergall M, Thomas R, Guyer A, Beach A, et al.  
669 Selection of *Candida albicans* trisomy during oropharyngeal infection results in  
670 a commensal-like phenotype. PLoS Genet. 2019;15.  
671 doi:10.1371/journal.pgen.1008137
- 672 29. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in  
673 drug-resistant *Candida albicans*. Science. 2006;313: 367–70.  
674 doi:10.1126/science.1128242
- 675 30. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J. An  
676 isochromosome confers drug resistance in vivo by amplification of two genes,  
677 ERG11 and TAC1. Mol Microbiol. 2008;68: 624–641. doi:10.1111/J.1365-  
678 2958.2008.06176.X
- 679 31. Dunn MJ, Anderson MZ. To repeat or not to repeat: Repetitive sequences  
680 regulate genome stability in *Candida albicans*. Genes (Basel). 2019;10.  
681 doi:10.3390/genes10110866
- 682 32. Todd RT, Wikoff TD, Forche A, Selmecki A. Genome plasticity in *Candida*  
683 *albicans* is driven by long repeat sequences. Elife. 2019;8.



- doi:10.7554/eLife.45954
33. Todd RT, Selmecki A. Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs. *Elife*. 2020;9: 1–33. doi:10.7554/eLife.58349
34. Hirakawa MP, Martinez DA, Sakthikumar S, Anderson MZ, Berlin A, Gujja S, et al. Genetic and phenotypic intra-species variation in *Candida albicans*. *Genome Res*. 2015;25: 413–25. doi:10.1101/gr.174623.114
35. Ene I V., Farrer RA, Hirakawa MP, Agwamba K, Cuomo CA, Bennett RJ. Global analysis of mutations driving microevolution of a heterozygous diploid fungal pathogen. *Proc Natl Acad Sci U S A*. 2018;115: E8688–E8697. doi:10.1073/pnas.1806002115
36. Freire-Benítez V, Gourlay S, Berman J, Buscaino A. Sir2 regulates stability of repetitive domains differentially in the human fungal pathogen *Candida albicans*. *Nucleic Acids Res*. 2016;44. doi:10.1093/nar/gkw594
37. Buscaino. Chromatin-Mediated Regulation of Genome Plasticity in Human Fungal Pathogens. *Genes (Basel)*. 2019;10: 855. doi:10.3390/genes10110855
38. Anderson MZ, Baller J a, Dulmage K, Wigen L, Berman J. The three clades of the telomere-associated TLO gene family of *Candida albicans* have different splicing, localization and expression features. *Eukaryot Cell*. 2012;11: 612–625. doi:10.1128/EC.00230-12
39. Haran J, Boyle H, Hokamp K, Yeomans T, Liu Z, Church M, et al. Telomeric ORFs (TLOs) in *Candida* spp. Encode Mediator Subunits That Regulate Distinct Virulence Traits. *PLoS Genet*. 2014;10: e1004658. doi:10.1371/journal.pgen.1004658
40. Zhang A, Petrov KO, Hyun ER, Liu Z, Gerber SA, Myers LC. The Tlo proteins are stoichiometric components of *Candida albicans* mediator anchored via the Med3 subunit. *Eukaryot Cell*. 2012;11: 874–84. doi:10.1128/EC.00095-12
41. Forche A, Abbey D, Pisithkul T, Weinzierl MA, Ringstrom T, Bruck D, et al. Stress alters rates and types of loss of heterozygosity in *Candida albicans*. *MBio*. 2011;2. doi:10.1128/mBio.00129-11

- 714 42. Harrison BD, Hashemi J, Bibi M, Pulver R, Bavli D, Nahmias Y, et al. A  
715 tetraploid intermediate precedes aneuploid formation in yeasts exposed to  
716 fluconazole. *PLoS Biol.* 2014;12: e1001815. doi:10.1371/journal.pbio.1001815
- 717 43. Forche A, Cromie G, Gerstein AC, Solis N V, Pisithkul T. Rapid Phenotypic  
718 and Genotypic Diversification After. 2018;209: 725–741.
- 719 44. Noble SM, French S, Kohn LA, Chen V, Johnson AD. Systematic screens of a  
720 *Candida albicans* homozygous deletion library decouple morphogenetic  
721 switching and pathogenicity. *Nat Genet.* 2010;42: 590–598.  
722 doi:10.1038/ng.605
- 723 45. Hakem R. DNA-damage repair; the good, the bad, and the ugly. *EMBO J.*  
724 2008;27: 589–605. doi:10.1038/emboj.2008.15
- 725 46. Aboussekhr A, Wood RD. Repair of UV-damaged DNA by mammalian cells  
726 and *Saccharomyces cerevisiae*. *Curr Opin Genet Dev.* 1994;4: 212–220.  
727 doi:10.1016/S0959-437X(05)80047-4
- 728 47. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with  
729 monofunctional alkylating agents. *Mutat Res - Fundam Mol Mech Mutagen.*  
730 1990;231: 11–30. doi:10.1016/0027-5107(90)90173-2
- 731 48. T W. DNA damage checkpoints update: getting molecular. *Curr Opin Genet*  
732 *Dev.* 1998;8: 185–193. doi:10.1016/S0959-437X(98)80140-8
- 733 49. L di C, BS C. DNA synthesis in UV-irradiated yeast. *Mutat Res.* 1981;82: 69–  
734 85. doi:10.1016/0027-5107(81)90139-1
- 735 50. Butler DK, All O, Govenia J, Loveless T, Wilson T, Toenjes KA. The *GRR1*  
736 gene of *Candida albicans* is involved in the negative control of pseudohyphal  
737 morphogenesis. *Fungal Genet Biol.* 2006;43: 573–582.  
738 doi:10.1016/j.fgb.2006.03.004
- 739 51. McCoy KM, Tubman ES, Claas A, Tank D, Clancy SA, O'Toole ET, et al.  
740 Physical limits on kinesin-5-mediated chromosome congression in the smallest  
741 mitotic spindles. *Mol Biol Cell.* 2015;26: 3999–4014. doi:10.1091/mbc.E14-10-  
742 1454
- 743 52. Enjalbert B, Smith DA, Cornell MJ, Alam I, Nicholls S, Brown AJP, et al. Role

- of the Hog1 Stress-activated Protein Kinase in the Global Transcriptional Response to Stress in the Fungal Pathogen *Candida albicans*. *Mol Biol Cell*. 2006;17: 1018. doi:10.1091/MBC.E05-06-0501
53. Bhaumik SR, Green MR. Differential requirement of SAGA components for recruitment of TATA-box-binding protein to promoters in vivo. *Mol Cell Biol*. 2002;22: 7365–7371. doi:10.1128/MCB.22.21.7365-7371.2002
54. Sterner DE, Belotserkovskaya R, Berger SL. SALSA, a variant of yeast SAGA, contains truncated Spt7, which correlates with activated transcription. *Proc Natl Acad Sci U S A*. 2002;99: 11622–11627. doi:10.1073/pnas.182021199
55. Hnisz D, Majer O, Frohner IE, Komnenovic V, Kuchler K. The Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of *Candida albicans*. *PLoS Pathog*. 2010;6: e1000889. doi:10.1371/journal.ppat.1000889
56. Ferreira T, Brèthes D, Pinson B, Napias C, Chevallier J. Functional analysis of mutated purine-cytosine permease from *Saccharomyces cerevisiae*. A possible role of the hydrophilic segment 371-377 in the active carrier conformation. *J Biol Chem*. 1997;272: 9697–9702. doi:10.1074/jbc.272.15.9697
57. Rousselet G, Simon M, Ripoche P, Buhler JM. A second nitrogen permease regulator in *Saccharomyces cerevisiae*. *FEBS Lett*. 1995;359: 215–219. doi:10.1016/0014-5793(95)00038-B
58. ElBerry HM, Majumdar ML, Cunningham TS, Sumrada RA, Cooper TG. Regulation of the urea active transporter gene (DUR3) in *Saccharomyces cerevisiae*. *J Bacteriol*. 1993;175: 4688–4698. doi:10.1128/jb.175.15.4688-4698.1993
59. Wichmann H, Hengst L, Gallwitz D. Endocytosis in yeast: Evidence for the involvement of a small GTP-binding protein (Ypt7p). *Cell*. 1992;71: 1131–1142. doi:10.1016/S0092-8674(05)80062-5
60. Talbert PB, Henikoff S. Histone variants--ancient wrap artists of the epigenome. *Nat Rev Mol Cell Biol*. 2010;11: 264–75. doi:10.1038/nrm2861

- 774 61. Yoshida S, Ohya Y, Goebel M, Nakano A, Anraku Y. A novel gene, STT4,  
775 encodes a phosphatidylinositol 4-kinase in the PKC1 protein kinase pathway of  
776 *Saccharomyces cerevisiae*. J Biol Chem. 1994;269: 1166–1171.  
777 doi:10.1016/s0021-9258(17)42237-x
- 778 62. Herrero AB, Magnelli P, Mansour MK, Levitz SM, Bussey H, Abeijon C. KRE5  
779 gene null mutant strains of *Candida albicans* are avirulent and have altered  
780 cell wall composition and hypha formation properties. Eukaryot Cell. 2004;3:  
781 1423–1432. doi:10.1128/EC.3.6.1423-1432.2004
- 782 63. Garvin AJ, Morris JR. SUMO, a small, but powerful, regulator of double-strand  
783 break repair. Philos Trans R Soc B Biol Sci. 2017;372.  
784 doi:10.1098/RSTB.2016.0281
- 785 64. Watts FZ. The role of SUMO in chromosome segregation. Chromosoma.  
786 2007;116: 15–20. doi:10.1007/s00412-006-0079-z
- 787 65. Cremona CA, Sarangi P, Zhao X. Sumoylation and the DNA Damage  
788 Response. Biomolecules. 2012;2: 376. doi:10.3390/BIOM2030376
- 789 66. Ryu HY, Ahn SH, Hochstrasser M. SUMO and cellular adaptive mechanisms.  
790 Exp Mol Med. 2020;52: 931–939. doi:10.1038/s12276-020-0457-2
- 791 67. Felberbaum R, Hochstrasser M. Ulp2 and the DNA damage response:  
792 Desumoylation enables safe passage through mitosis. Cell Cycle. 2008;7: 52–  
793 56. doi:10.4161/cc.7.1.5218
- 794 68. Jaiswal D, Turniansky R, Green EM. Choose your own adventure: The role of  
795 histone modifications in yeast cell fate. J Mol Biol. 2017;429: 1946.  
796 doi:10.1016/J.JMB.2016.10.018
- 797 69. LD V, K G, I DS. Protein Language: Post-Translational Modifications Talking to  
798 Each Other. Trends Plant Sci. 2018;23: 1068–1080.  
799 doi:10.1016/J.TPLANTS.2018.09.004
- 800 70. Morrell R, Sadanandom A. Dealing With Stress: A Review of Plant SUMO  
801 Proteases. Front Plant Sci. 2019;10: 1–19. doi:10.3389/fpls.2019.01122
- 802 71. K D. Ubiquitin and SUMO Modifications in *Caenorhabditis elegans* Stress  
803 Response. Curr Issues Mol Biol. 2020;35: 145–158.

- doi:10.21775/CIMB.035.145
72. JS S, A D. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17: 184–197. doi:10.1038/NRC.2016.143
73. Brown AJP, Budge S, Kaloriti D, Tillmann A, Jacobsen MD, Yin Z, et al. Stress adaptation in a pathogenic fungus. J Exp Biol. 2014;217: 144–155. doi:10.1242/jeb.088930
74. Leach MD, Stead DA, Argo E, Brown AJP. Identification of sumoylation targets, combined with inactivation of SMT3, reveals the impact of sumoylation upon growth, morphology, and stress resistance in the pathogen *Candida albicans*. Mol Biol Cell. 2011;22: 687–702. doi:10.1091/mbc.E10-07-0632
75. Bianchis V, Pontis E, Reichard P. THE JOURNAL OF BIOLOGICAL CHEMISTRY Changes of Deoxyribonucleoside Triphosphate Pools Induced by Hydroxyurea and Their Relation to DNA Synthesis\*. J Biol Chem. 1986;261: 16037–16042. doi:10.1016/S0021-9258(18)66672-4
76. Huaping L, Jie L, Zhifeng W, Yingchang Z, Yuhuan L. Cloning and functional expression of ubiquitin-like protein specific proteases genes from *Candida albicans*. Biol Pharm Bull. 2007;30: 1851–1855. doi:10.1248/bpb.30.1851
77. Segal ES, Gritsenko V, Levitan A, Yadav B, Dror N, Steenwyk JL, et al. Gene Essentiality Analyzed by In Vivo Transposon Mutagenesis and Machine Learning in a Stable Haploid Isolate of *Candida albicans*. MBio. 2018;9: e02048-18. doi:10.1128/MBIO.02048-18
78. O’Meara TR, Hay C, Price MS, Giles S, Alspaugh JA. *Cryptococcus neoformans* histone acetyltransferase Gcn5 regulates fungal adaptation to the host. Eukaryot Cell. 2010;9: 1193–202. doi:10.1128/EC.00098-10
79. Berman J. Morphogenesis and cell cycle progression in *Candida albicans* Curr. Curr Opin Microbiol. 2006;9: 595–601. doi:10.1016/j.mib.2006.10.007.Morphogenesis
80. Loll-Kripplbeier R, d’Enfert C, Feri A, Diogo D, Perin A, Marcet-Houben M, et al. A study of the DNA damage checkpoint in *Candida albicans*: uncoupling of the functions of Rad53 in DNA repair, cell cycle regulation and genotoxic

- 834 stress-induced polarized growth. *Mol Microbiol.* 2014;91: 452–471.  
835 doi:10.1111/mmi.12471
- 836 81. Legrand M, Chan CL, Jauert PA, Kirkpatrick DT. The contribution of the S-  
837 phase checkpoint genes MEC1 and SGS1 to genome stability maintenance in  
838 *Candida albicans*. *Fungal Genet Biol.* 2011;48: 823–30.  
839 doi:10.1016/j.fgb.2011.04.005
- 840 82. Burrack LS, Applen Clancey SE, Chacón JM, Gardner MK, Berman J.  
841 Monopolin recruits condensin to organize centromere DNA and repetitive DNA  
842 sequences. *Mol Biol Cell.* 2013;24: 2807–19. doi:10.1091/mbc.E13-05-0229
- 843 83. Ryu HY, Wilson NR, Mehta S, Hwang SS, Hochstrasser M. Loss of the SUMO  
844 protease ULP2 triggers a specific multichromosome aneuploidy. *Genes Dev.*  
845 2016;30: 1881–1894. doi:10.1101/gad.282194.116
- 846 84. Ryu HY, López-Giráldez F, Knight J, Hwang SS, Renner C, Kreft SG, et al.  
847 Distinct adaptive mechanisms drive recovery from aneuploidy caused by loss  
848 of the Ulp2 SUMO protease. *Nat Commun.* 2018;9. doi:10.1038/s41467-018-  
849 07836-0
- 850 85. Ma Q, Ola M, Iracane E, Butler G. Susceptibility to Medium-Chain Fatty Acids  
851 Is Associated with Trisomy of Chromosome 7 in *Candida albicans* . *mSphere.*  
852 2019;4. doi:10.1128/MSPHERE.00402-19
- 853 86. Calvo IA, Gabrielli N, Iglesias-Baena I, García-Santamarina S, Hoe K-L, Kim  
854 DU, et al. Genome-Wide Screen of Genes Required for Caffeine Tolerance in  
855 Fission Yeast. *PLoS One.* 2009;4: e6619.  
856 doi:10.1371/JOURNAL.PONE.0006619
- 857 87. Pfaller M a. Antifungal drug resistance: mechanisms, epidemiology, and  
858 consequences for treatment. *Am J Med.* 2012;125: S3-13.  
859 doi:10.1016/j.amjmed.2011.11.001
- 860 88. Bruno VM, Mitchell AP. Regulation of azole drug susceptibility by *Candida*  
861 *albicans* protein kinase CK2. *Mol Microbiol.* 2005;56: 559–573.  
862 doi:10.1111/j.1365-2958.2005.04562.x
- 863 89. Goodwin TJD, Poulter RTM. Multiple LTR-retrotransposon families in the

- 864 asexual yeast *Candida albicans*. *Genome Res.* 2000;10: 174–191.  
865 doi:10.1101/gr.10.2.174
- 866 90. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B.  
867 *Candida albicans* zinc cluster protein Upc2p confers resistance to antifungal  
868 drugs and is an activator of ergosterol biosynthetic genes. *Antimicrob Agents*  
869 *Chemother.* 2005;49: 1745–1752. doi:10.1128/AAC.49.5.1745-1752.2005
- 870 91. Silver PM, Oliver BG, White TC. Role of *Candida albicans* transcription factor  
871 Upc2p in drug resistance and sterol metabolism. *Eukaryot Cell.* 2004;3: 1391–  
872 1397. doi:10.1128/EC.3.6.1391-1397.2004/ASSET/112DA7BA-82B3-42CB-  
873 BDEB-198E91B9521D/ASSETS/GRAPHIC/ZEK0060423520006.JPEG
- 874 92. Miller JE, Reese JC. Ccr4-Not complex: the control freak of eukaryotic cells.  
875 *Crit Rev Biochem Mol Biol.* 2012;47: 315. doi:10.3109/10409238.2012.667214
- 876 93. Islam A, Tebbji F, Mallick J, Regan H, Dumeaux V, Omran RP, et al. Mms21:  
877 A putative SUMO E3 ligase in *Candida albicans* that negatively regulates  
878 invasiveness and filamentation, and is required for the genotoxic and cellular  
879 stress response. *Genetics.* 2019;211: 579–595.  
880 doi:10.1534/genetics.118.301769
- 881 94. Omeara TR, Veri AO, Ketela T, Jiang B, Roemer T, Cowen LE. Global  
882 analysis of fungal morphology exposes mechanisms of host cell escape. *Nat*  
883 *Commun.* 2015;6: 1–10. doi:10.1038/ncomms7741
- 884 95. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO  
885 proteases. *Nat Rev Mol Cell Biol.* 2012;13: 755–766. doi:10.1038/nrm3478
- 886 96. Suhandynata RT, Quan Y, Yang Y, Yuan W-T, Albuquerque CP, Zhou H.  
887 Recruitment of the Ulp2 protease to the inner kinetochore prevents its hyper-  
888 sumoylation to ensure accurate chromosome segregation. *PLOS Genet.*  
889 2019;15: e1008477. doi:10.1371/JOURNAL.PGEN.1008477
- 890 97. Miyagawa K, Low RS, Santosa V, Tsuji H, Moser BA, Fujisawa S, et al.  
891 SUMOylation regulates telomere length by targeting the shelterin subunit  
892 Tpz1Tpp1 to modulate shelterin–Stn1 interaction in fission yeast. *Proc Natl*  
893 *Acad Sci.* 2014;111: 5950–5955. doi:10.1073/PNAS.1401359111



- 984 98. Montpetit B, Hazbun TR, Fields S, Hieter P. Sumoylation of the budding yeast  
985 kinetochore protein Ndc10 is required for Ndc10 spindle localization and  
986 regulation of anaphase spindle elongation. *J Cell Biol.* 2006;174: 653–663.  
987 doi:10.1083/jcb.200605019
- 988 99. Barra V, Fachinetti D. The dark side of centromeres: types, causes and  
989 consequences of structural abnormalities implicating centromeric DNA. *Nat*  
990 *Commun.* 2018;9. doi:10.1038/s41467-018-06545-y
- 991 100. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al.  
992 Massive genomic rearrangement acquired in a single catastrophic event during  
993 cancer development. *Cell.* 2011;144: 27–40. doi:10.1016/j.cell.2010.11.055
- 994 101. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, et al.  
995 Gain-of-function mutations in UPC2 are a frequent cause of ERG11  
996 upregulation in azole-resistant clinical isolates of *Candida albicans*. *Eukaryot*  
997 *Cell.* 2012;11: 1289–1299. doi:10.1128/EC.00215-12
- 998 102. Collart MA. The Ccr4-Not complex is a key regulator of eukaryotic gene  
999 expression. *Wiley Interdiscip Rev RNA.* 2016;7: 438–454.  
1000 doi:10.1002/WRNA.1332
- 1001 103. Wilson RB, Davis D, Mitchell AP. Rapid hypothesis testing with *Candida*  
1002 *albicans* through gene disruption with short homology regions. *J Bacteriol.*  
1003 1999;181: 1868–74. Available: <http://www.ncbi.nlm.nih.gov/pubmed/10074081>
- 1004 104. von der Haar T. Optimized protein extraction for quantitative proteomics of  
1005 yeasts. *PLoS One.* 2007;2: e1078. doi:10.1371/journal.pone.0001078
- 1006 105. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina  
1007 sequence data. *Bioinformatics.* 2014;30: 2114–2120.  
1008 doi:10.1093/BIOINFORMATICS/BTU170
- 1009 106. Li H. Aligning sequence reads, clone sequences and assembly contigs with  
1010 BWA-MEM. 2013 [cited 17 Nov 2021]. Available:  
1011 <https://arxiv.org/abs/1303.3997v2>
- 1012 107. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler  
1013 transform. *Bioinformatics.* 2009;25: 1754–1760.

doi:10.1093/bioinformatics/btp324

108. Okonechnikov K, Conesa A, García-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. *Bioinformatics*. 2016;32: 292–294. doi:10.1093/BIOINFORMATICS/BTV566
109. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013 313. 2013;31: 213–219. doi:10.1038/nbt.2514
110. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)*. 2012;6: 80–92. doi:10.4161/fly.19695
111. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform*. 2013;14: 178–192. doi:10.1093/BIB/BBS017
112. Abbey D a, Funt J, Lurie-Weinberger MN, Thompson D a, Regev A, Myers CL, et al. YMAP: a pipeline for visualization of copy number variation and loss of heterozygosity in eukaryotic pathogens. *Genome Med*. 2014;6: 1–15. doi:10.1186/s13073-014-0100-8
113. Schwartz DC, Cantor CR. Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. *Cell*. 1984;37: 67–75. doi:10.1016/0092-8674(84)90301-5

## Figure Legends

### Fig 1. *ULP2* is a regulator of *C. albicans* genotoxic stress response

(A) Schematic representation of the screening strategy. 674 *C. albicans* deletion strains were screened using a 96-plate format for hypersensitivity to UV and MMS. Hypersensitivity was scored by comparing the growth of treated vs untreated on a scale of 0 (white) to 4 (magenta). Black \*: genes encoding for DNA damage and sensing repair pathway components, Blue \*: genes encoding for cell division and chromosome segregation machinery, Green arrow: *ulp2*  $\Delta/\Delta$  (B) Data for a plate containing *mec3*  $\Delta/\Delta$  strain (cyan circle). Growth on Non-selective (N/S) media or following UV and MMS treatment is shown. (C) Data for a plate containing *ulp2*  $\Delta/\Delta$  strain (magenta circle). Growth on Non-selective (N/S) media or following UV and MMS treatment is shown (D) Colony-forming Unit assay of UV treated WT and *ulp2*  $\Delta/\Delta$  strains. % survival is shown. (E) Growth curve on WT and *ulp2*  $\Delta/\Delta$  strains grown in non-selective (N/S) liquid media and MMS-containing liquid media. Error bars: standard deviation (SD) of three biological replicates (F) Growth curve on WT and *ulp2*  $\Delta/\Delta$  strains grown in non-selective (N/S) liquid media and HU-containing liquid media.

### Fig 2. *ULP2* is necessary for survival under stress

(A) Schematic representation of Ulp1, Ulp2 and Ulp3 protein organisation. The systematic name and the amino acid (aa) number is indicated for each protein. Blue box: putative catalytic UD domain typical of Ulp SUMO proteases (B) Protein alignments of the three *C. albicans* Ulp proteins (Ulp1, Ulp2 and Ulp3) and the two *S. cerevisiae* proteins (Ulp1 and Ulp2). Magenta arrows: amino acids essential for SUMO protease activity (C) HA Western Blot analysis of 4 independent ULP2-HA integrants and the progenitor untagged control (No Tag). Magenta arrow: Ulp2-HA (Magenta arrow). \*: non-specific cross-reacting bands serving as a loading control (D) Growth curves of WT, *ulp1*  $\Delta/\Delta$  and *ulp2*  $\Delta/\Delta$  strains grown in non-selective (N/S) liquid media. Error bars: standard deviation (SD) of three biological replicates (E) Serial dilution assay of WT, *ulp1*  $\Delta/\Delta$  and *ulp2*  $\Delta/\Delta$  strains grown in unstressed (N/S) or stress (UV, MMS, HU, H2O2 and 39 °C) growth conditions.

### Fig 3. Loss of *ULP2* leads to increased genome instability

**(A)** Quantification of loss of a heterozygous *URA3*<sup>+</sup> marker gene inserted in Chr1, Chr3 and Chr7 in WT and *ulp2*  $\Delta/\Delta$  strain. A fold difference of *URA3*<sup>+</sup> marker loss between *ulp2*  $\Delta/\Delta$  and WT strains is indicated. \*\*: Chr1 (4.11E-07) and Chr7 (6.74E-05) p-value, \*: Chr3 (2.87E-02) p-value **(B)** *Top*: Representative images displaying the morphologies of WT and *ulp2*  $\Delta/\Delta$  strains. *Bottom*: Quantification (%) of yeast and filamentous (hyphae + pseudohyphae) cells in WT and *ulp2*  $\Delta/\Delta$  strains. Error bar: Standard deviation of 3 biological replicates. **(C)** *Top*: schematics of the CEN7 TetO and TetR-GFP system. *Bottom*: nuclear morphology and segregation pattern of centromere 7 (*CEN7*) in WT and *ulp2*  $\Delta/\Delta$  strain. Quantification (%) of abnormal GFP-CEN7 patterns is indicated. Error bar: Standard deviation of 3 biological replicates. **(D)** Whole genome sequencing analysis of the progenitor (SN152) and three single colonies C1, C2, and C3. Data were plotted as the log2 ratio and converted to chromosome copy number (y-axis, 1-4 copies) as a function of chromosome position (x-axis, Chr1-ChrR) using the Yeast Mapping Analysis Pipeline (YMAP) [112]. Heterozygous (AB) regions are indicated with grey shading, and homozygous regions (loss of heterozygosity) are indicated by shading of the remaining haplotype, either AA (cyan) or BB (magenta). Two homozygous positions are present in the progenitor (the left side of Chr2 and a small region near the centromere of Chr3), while C1 and C2 underwent loss of heterozygosity of ChrR and Chr3.

#### **Fig 4. Loss of ULP2 leads to drug resistance via selection of novel genotypes**


**(A)** Serial dilution assay of WT and *ulp2*  $\Delta/\Delta$  strains grown in non-selective (N/S) or media containing low (15  $\mu$ g/ml) concentration of fluconazole (FLC). **(B)** Serial dilution assay of WT and *ulp2*  $\Delta/\Delta$  strains grown in non-selective (N/S) or media containing low (5 mM) Caffeine (CAF). **(C)** *Left*: Plating assay of *ulp2*  $\Delta/\Delta$  and WT strain in media containing high (128  $\mu$ g/ml) concentration of fluconazole (FLC) or non-selective (NS) media *Right*: Plating assay quantification. The number of large (L) and small (S) colonies recovered from fluconazole (FLC) containing media and non-selective (N/S) media is shown for WT and *ulp2*  $\Delta/\Delta$  strains. **(D)** *Left*: Plating assay of *ulp2*  $\Delta/\Delta$  and WT strain in media containing high (12 mM) concentration of caffeine (CAF) and non-selective (NS) media *Right*: Plating assay quantification. The number of large (L) and small (S) colonies recovered from caffeine (CAF)-containing

1011 media and non-selective (N/S) media is shown for WT and *ulp2*  $\Delta/\Delta$  strains. **(E)**  
1012 Whole genome sequencing data plotted as in Figure 3D for four single colonies  
1013 isolated from 128  $\mu$ g/ml fluconazole plates (*FLC1-FLC4*). The chromosome copy  
1014 number is plotted along the y-axis (1-4 copies). All four single colonies have a  
1015 recurrent segmental deletion of part of ChrRR. Colony *FLC-4* has an amplification of  
1016 the middle part of Chr1. Copy number breakpoints and allele ratio changes in *FLC-4*  
1017 are indicated in Figure S3. **(F)** CHEF karyotype gel stained with ethidium bromide of  
1018 *ulp2*  $\Delta/\Delta$  progenitor and *FLC-4* isolate. A band (blue \*) corresponding to Chr6 is  
1019 present in the *ulp2*  $\Delta/\Delta$  progenitor and absent in the *FLC-4* isolate. Conversely, a  
1020 new band (magenta \*) is present in the *FLC-4* isolate but absent in the *ulp2*  
1021  $\Delta/\Delta$  progenitor. **(G)** Schematics of segmental aneuploidies detected in *FLC-1*, *FLC-2*,  
1022 *FLC-3* and *FLC-4* isolates.


1023




A




B




C




D




E




F




A




B




C



D



E









## Fig 3

bioRxiv preprint doi: <https://doi.org/10.1101/2021.12.06.471441>; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

A



C



D





Fig 4


A




B




C




D



E



F



G

